Tychan Pte Ltd.
🇸🇬Singapore
- Country
- 🇸🇬Singapore
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.tychan.com
Clinical Trials
4
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:3
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 3
1 (25.0%)Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans
Phase 3
Terminated
- Conditions
- Coronavirus Disease-2019 (COVID-19)
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Tychan Pte Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT04649515
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
Safety of TY027, a Treatment for COVID-19, in Humans
Phase 1
Completed
- Conditions
- Coronavirus Disease-2019 (COVID-19)
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Tychan Pte Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04429529
- Locations
- 🇸🇬
SingHealth Investigational Medicine Unit, Singapore, Singapore
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients
Phase 1
Withdrawn
- Conditions
- Treatment of Acute Zika Virus Infection
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Tychan Pte Ltd.
- Registration Number
- NCT03776695
- Locations
- 🇸🇬
SingHealth Investigational Medicine Unit, Singapore, Singapore
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Tychan Pte Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03443830
- Locations
- 🇸🇬
SingHealth Investigational Medicine Unit, Singapore, Singapore
News
No news found